AU2001294515A1 - Use of stat-6 inhibitors as therapeutic agents - Google Patents
Use of stat-6 inhibitors as therapeutic agentsInfo
- Publication number
- AU2001294515A1 AU2001294515A1 AU2001294515A AU9451501A AU2001294515A1 AU 2001294515 A1 AU2001294515 A1 AU 2001294515A1 AU 2001294515 A AU2001294515 A AU 2001294515A AU 9451501 A AU9451501 A AU 9451501A AU 2001294515 A1 AU2001294515 A1 AU 2001294515A1
- Authority
- AU
- Australia
- Prior art keywords
- stat
- inhibitors
- therapeutic agents
- therapeutic
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/637,531 | 2000-08-11 | ||
US09/637,531 US6696441B1 (en) | 2000-08-11 | 2000-08-11 | Inhibition of p53-induced stress response |
US30134001P | 2001-06-26 | 2001-06-26 | |
US60/301,340 | 2001-06-26 | ||
PCT/US2001/025175 WO2002014321A1 (en) | 2000-08-11 | 2001-08-10 | Use of stat-6 inhibitors as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001294515A1 true AU2001294515A1 (en) | 2002-02-25 |
Family
ID=26972310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001294515A Abandoned AU2001294515A1 (en) | 2000-08-11 | 2001-08-10 | Use of stat-6 inhibitors as therapeutic agents |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001294515A1 (en) |
WO (1) | WO2002014321A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076439A2 (en) * | 2001-03-23 | 2002-10-03 | The Board Of Trustees Of The University Of Illinois | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
WO2002088107A1 (en) * | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
FR2910895B1 (en) * | 2006-12-29 | 2010-08-27 | Biopharmed | "IMINO-TETRAHYDROBENZOTRIAZOLES DERIVATIVES HAVING ANTI-MIGRATORY PROPERTIES OF DEPENDENT METASTASES" |
WO2008155441A1 (en) * | 2007-06-20 | 2008-12-24 | Marikki Laiho | Activators and therapeutic applications thereof |
US8188083B2 (en) | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
EP2218464A1 (en) * | 2009-02-11 | 2010-08-18 | Technische Universität München | Compounds for non-invasive measurement of aggregates of amyloid peptides |
US8569002B2 (en) | 2010-10-20 | 2013-10-29 | The Board Of Regents Of The University Of Texas System | Multiplexed luciferase reporter assay systems |
WO2015027431A1 (en) * | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
TWI648282B (en) * | 2014-03-27 | 2019-01-21 | 印度商托仁特生技有限公司 | New fusion imidazole benzothiazole compound |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3377488T3 (en) | 2015-11-19 | 2022-12-19 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3394033T2 (en) | 2015-12-22 | 2021-04-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MY197280A (en) | 2016-06-20 | 2023-06-09 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2899402T3 (en) | 2016-12-22 | 2022-03-11 | Incyte Corp | Pyridine derivatives as immunomodulators |
MD3558990T2 (en) | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as PD-L1 internalization inducers |
KR20190111025A (en) | 2016-12-22 | 2019-10-01 | 인사이트 코포레이션 | Benzoxazole Derivatives As Immunomodulators |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
PE20211911A1 (en) | 2018-03-30 | 2021-09-28 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
JOP20200288A1 (en) | 2018-05-11 | 2020-11-11 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
AR119624A1 (en) | 2019-08-09 | 2021-12-29 | Incyte Corp | SALTS OF A PD-1/PD-L1 INHIBITOR |
EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
KR20220101664A (en) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Salts and crystalline forms of PD-1/PD-L1 inhibitors |
PE20231438A1 (en) | 2020-11-06 | 2023-09-14 | Incyte Corp | PROCESS FOR MAKING A PD-1/PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185446A (en) * | 1990-09-04 | 1993-02-09 | Neurogen Corporation | Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands |
JPH11106340A (en) * | 1997-10-02 | 1999-04-20 | Sumitomo Pharmaceut Co Ltd | Stat6 activation inhibitor |
EP1143943B1 (en) * | 1999-01-29 | 2007-12-12 | The Board Of Trustees Of The University Of Illinois | USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY |
-
2001
- 2001-08-10 AU AU2001294515A patent/AU2001294515A1/en not_active Abandoned
- 2001-08-10 WO PCT/US2001/025175 patent/WO2002014321A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2002014321A9 (en) | 2003-03-27 |
WO2002014321A1 (en) | 2002-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001294515A1 (en) | Use of stat-6 inhibitors as therapeutic agents | |
AU2002334969A1 (en) | Use of stat-6 inhibitors as therapeutic agents | |
GB0025782D0 (en) | Use of inhibitors | |
AU2001269046A1 (en) | Use of therapeutic benzamide derivatives | |
AU2002322719A1 (en) | Delivery of therapeutic capable agents | |
HRP20041029A2 (en) | Therapeutic use of selcetive pde10 inhibitors | |
HK1091840A1 (en) | Methods and compositions for therapeutic use of rna interference | |
AU2003261251A1 (en) | Methods of delivering therapeutic agents | |
IL149106A0 (en) | Therapeutic use of selective pde10 inhibitors | |
GB0010183D0 (en) | Inhibitors of dipeptidyl peptidase IV | |
HUP0300061A3 (en) | Use of il-18 inhibitors | |
AU2002338806A1 (en) | Pharmaceutical combinations of pde-v inhibitors and other agents | |
AU8969601A (en) | New use of lipase inhibitors | |
AU2001228703A1 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
AU2002338734A1 (en) | Use of phosphorodiesterase IV inhibitors | |
AU1929301A (en) | Methods of use of peptide deformylase inhibitors as novel antibacterial agents | |
HUP0401641A3 (en) | Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors | |
IL131047A0 (en) | Use of il-18 inhibitors | |
AU2001274344A1 (en) | Tissue inhibitors of matrix metalloproteinases | |
IL160230A0 (en) | Use of il-18 inhibitors | |
AU2002221882A1 (en) | Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors | |
AU1212002A (en) | Use of lipase inhibitors | |
AU4021700A (en) | Methods of use of beta1-integrin inhibitors | |
AU2002305868A1 (en) | Inhibitors of reggamma | |
AU2001283964A1 (en) | Composition for combined use of aromatase inhibitors |